It is generally recognised that early diagnosis of cancer leads to increased survival rates. The Cancer Diagnostic Technology Summit (11- 14 May) brings together the best in academic research and commercial leaders to examine how near we are to achieving the ideal cancer diagnostic tests.
New speakers join Cancer Diagnostic Summit
When most cancers are diagnosed at Stages 3 or 4, there is an urgent need for better diagnostic methods which are: more sensitive, inexpensive, non-invasive, capable of being used in a doctor's office or home setting, and accepted by patients. The Cancer Diagnostic Technology Summit brings together the best in academic research and commercial leaders to examine how near we are to achieving the ideal cancer diagnostic tests.
Four new speakers have joined the programme at the Cancer Diagnostic Technology Summit, being held each afternoon (UK time) from 11 - 14 May:
Dr Dana Al-Sulaiman is a Research Associate in Chemical Engineering at Massachusetts Insitute of Technology. She will discuss hydrogels for cancer diagnosis in the Advanced Technology session
Dr Sofia Birkeälv is a Molecular Diagnostics Scientist at SAGA Diagnostics, Sweden: "Ultrasensitive cancer mutation detection, MRD monitoring, and liquid biopsies" in the Liquid Biopsy Session
Dr Jacqui Stockley is Chief Scientific Officer at Arquer Diagnostics: Liquid biopsy in urine for endometrial cancer.
Prof George Hanna, Head of Department of Surgery and Cancer, Imperal College: Breath biopsy for diagnosis of gastric cancer.
Liquid Biopsy | VOC Biomarkers | Pathways to earlier diagnosis in the UK | Cell Separation
Advanced Diagnostic Technology | Imaging | Artificial Intelligence
Pre-view the Conference as a slide show HERE
Captum Capital is an innovative consulting company, which facilitates the development of emerging life science companies. Captum provides MasterClasses in technology valuation and business modelling. The company founded Sensor100, an international network of people and organisations active in the development and commercialisation of bio- and chemo-sensors.